Moderna reduces 2025 revenue forecast as COVID vaccine demand wanesJanuary 13, 2025 Moderna stock dropped 18% after the company slashed its 2025 revenue forecast by $1 billion, citing declining COVID vaccine demand, market competition, and other financial challenges.
